Enfusion, Inc. (NYSE:ENFN) CFO Sells $259,340.23 in Stock

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $10.61, for a total transaction of $259,340.23. Following the sale, the chief financial officer now owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Enfusion Trading Up 1.0 %

ENFN traded up $0.11 during trading on Thursday, hitting $10.69. The company’s stock had a trading volume of 557,061 shares, compared to its average volume of 390,816. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of 267.32, a P/E/G ratio of 3.98 and a beta of 0.97. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $11.38. The business’s fifty day simple moving average is $9.80 and its 200 day simple moving average is $9.04.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ENFN. TenCore Partners LP acquired a new position in Enfusion in the third quarter valued at approximately $3,938,000. Dimensional Fund Advisors LP grew its holdings in Enfusion by 57.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after acquiring an additional 191,436 shares in the last quarter. Impax Asset Management Group plc raised its stake in Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after buying an additional 136,948 shares in the last quarter. Scalar Gauge Management LLC lifted its stake in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Enfusion in the 3rd quarter valued at $892,000. 81.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ENFN. Piper Sandler boosted their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday. Stifel Nicolaus raised their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Enfusion currently has a consensus rating of “Hold” and a consensus price target of $10.25.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.